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ABSTRACT
Introduction: This analysis aimed to
investigate the effectiveness and safety profile
of pirfenidone for the treatment of idiopathic
pulmonary fibrosis (IPF) in clinical practice.
Methods: Clinical records of patients diagnosed
with mild-to-moderate IPF (as per European
Medicines Agency indication) and receiving
pirfenidone treatment across three centers in
Belgium and the Netherlands between April
2011 and October 2013 were retrospectively
collected from patient notes at 3-month
intervals. Pulmonary function measurements,
including % predicted forced vital capacity
(%FVC) and % predicted diffusing capacity of
the lungs for carbon monoxide (%DLCO), were
analyzed from 6 months prior to pirfenidone
treatment up to 12 months of treatment.
Decline in lung function, defined as an
absolute C10% decline in FVC from baseline
or death at 12 months, was also analyzed. Safety
data were included for all follow-up visits.
Results: In the pooled cohort (n = 63), patients
were mostly men (84.1%) and current or former
smokers (79.4%). Average baseline %FVC and
%DLCO were 75.0% and 47.9%, respectively.
69.8% of patients had a high-resolution
computed tomography scan with a definite
usual interstitial pneumonia pattern, and 46%
had a surgical lung biopsy. The mean decline in
%FVC for 32 patients with available data was
4.8% from -6 months to baseline (p = 0.002)
and 0.8% from baseline to 6 months
(p = 0.516). Across these time intervals, a lesser
decline in DLCO was similarly observed during
therapy. At 12 months, ten patients had an
%FVC decline C10% or died. Loss of appetite
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(25.3%) and nausea (11.1%) were the most
frequent gastrointestinal side effects. Nausea
was the most highly cited reason for
discontinuation (7.9%).
Conclusions: In this clinical practice cohort,
pirfenidone showed effectiveness and safety
profiles consistent with those seen in the
Phase III clinical study ASCEND
(ClinicalTrials.gov #NCT01366209). These
results highlight the challenges and benefits
associated with pirfenidone treatment in
clinical practice.
Keywords: Case study; Esbriet; Forced vital
capacity; FVC; Idiopathic pulmonary fibrosis;
IPF; Named patient program; NPP; Pirfenidone
INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is a rare,
progressive, irreversible and ultimately fatal
chronic lung disease, with a median survival
time of 2–5 years [1–4]. It is the most common
of the idiopathic interstitial pneumonias and its
incidence and prevalence appear to be rising. In
the UK, disease incidence during the 2006–2008
calendar period was 5.10 cases per 100,000
person-years, which was sixfold higher than
during the 1968–1972 calendar period (0.92
cases per 100,000 person-years) [5]. In the USA,
annual incidence of IPF in the Medicare
population remained stable between 2001 and
2011, with an overall estimate of 93.7 cases per
100,000 person-years, while the annual
cumulative prevalence increased steadily from
202.2 cases per 100,000 in 2001 to 494.5 cases
per 100,000 in 2011 [6].
Pirfenidone is an oral anti-fibrotic drug with
anti-inflammatory properties and was the first
drug approved for the treatment of adult
patients with IPF by the European Medicines
Agency (EMA) in 2011, followed by approval by
the Food and Drug Administration (FDA) in
2014 [5, 6]. Nintedanib, a tyrosine kinase
inhibitor, has since been approved for IPF by
the FDA [7] and the EMA [8] (in 2014 and 2015,
respectively).
Pirfenidone has been studied in four Phase
III clinical trials: three multinational studies
[CAPACITY 004 (ClinicalTrials.gov
#NCT00287716) and 006 (ClinicalTrials.gov
#NCT00287729), and ASCEND
(ClinicalTrials.gov #NCT01366209)] and one
Japanese study [9–11]. Compared with
placebo, pirfenidone treatment was shown to
reduce forced vital capacity (FVC) decline,
reduce decline in 6-min walk test distance and
increase progression-free survival. Data from the
randomized, double-blind placebo-controlled
trial, ASCEND, were published in May 2014
[11]. In 555 patients with IPF, pirfenidone
slowed disease progression compared with
placebo; there was a relative reduction of
47.9% in the proportion of patients who had
an absolute decline of C10% in the % predicted
FVC (%FVC) or who died. A pre-specified
pooled analysis of the CAPACITY and ASCEND
studies at 52 weeks (12 months) showed that
treatment with pirfenidone significantly
reduced all-cause mortality by 48% [hazard
ratio (HR) 0.52, 95% confidence interval (CI)
0.31–0.87, p = 0.01] and IPF-related mortality
by 68% (HR 0.32, 95% CI 0.14–0.76, p = 0.006)
[11].
The most commonly reported adverse
reactions during clinical study experience with
pirfenidone compared with placebo were
nausea (32.4% vs. 12.2%), rash (26.2% vs.
7.7%), diarrhea (18.8% vs. 14.4%), fatigue
(18.5% vs. 10.4%), dyspepsia (16.1% vs. 5.0%),
anorexia (11.4% vs. 3.5%), headache (10.1% vs.
7.7%), and photosensitivity reaction (9.3% vs.
1.1%), respectively [12].
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Randomized controlled trials have long been
considered the gold standard for generating
clinical data. However, given the
standardization required, such as the
requirement for a robust trial design with
clearly defined inclusion and exclusion
criteria, such trials do not capture all
information that is relevant for clinical
practice. Indeed, real-world clinical experience
can provide important complementary
information on the use of investigational/new
treatments. Both clinical experience with
pirfenidone for the treatment of IPF, and
information available for health-care
professionals concerning the use of
pirfenidone in daily clinical practice, are
important to communicate, especially as the
literature is currently sparse on these topics.
Here, we report early clinical experiences of
the management of IPF treated with
pirfenidone at three centers in Belgium and
the Netherlands and compare these data with
results from a recent Phase III study (ASCEND).
METHODS
The Named Patient Program
To facilitate patient access to pirfenidone in
European countries where it was not
immediately available following EU approval,
InterMune International AG offered pirfenidone
(Esbriet, Roche, Basel, Switzerland) to
individual patients upon the request of their
treating physician in the context of a European
named patient program (NPP, known as Medical
Need Program in Belgium according to national
legislation). This program terminated once
pirfenidone became commercially available in
the participating European countries.
In Belgium and the Netherlands, eligible
patients (see criteria below) were informed by
their treating pulmonologist about the
possibility of entering the NPP to obtain
treatment with pirfenidone.
Data from enrolled patients were
retrospectively collected from three centers
(two in the Netherlands and one in Belgium)
between April 2011 and October 2013 (2 years
of analyzable data were available).
Patients
Eligible patients were diagnosed with IPF
according to the American Thoracic Society
and European Respiratory Society guidelines
[4], which include a multidisciplinary
diagnostic approach involving clinical,
radiological and, if necessary,
histopathological findings.
Inclusion criteria for this retrospective
analysis comprised a diagnosis of IPF with
%FVC C50 and % predicted diffusing capacity
for carbon monoxide (%DLCO) C30. Patients
with severe renal impairment (creatinine
clearance rate below 30 mL/min), severe
hepatic impairment, or with alcohol
dependence were excluded from the program.
Patient permissions for data collection and
usage were granted according to specific local
requirements of the medical ethical committee
at each participating center.
Treatment
Pirfenidone was given orally with food. The
initial dose of one capsule (267 mg pirfenidone)
three times per day (801 mg/day; 3 9 1) was
increased after 1 week to two capsules, three
times per day (1602 mg/day; 3 9 2), and after
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another week to the full approved maintenance
dose of three capsules, three times per day
(2403 mg/day; 3 9 3) [12].
Dose modifications to manage adverse
events (AEs) were adopted on an individual
patient basis and involved a down-titration
from the full 3 9 3 dosing regimen to a 3 9 2
or 3 9 1 regimen, or an individual scheme, with
dosing sometimes re-adjusted after the initial
modification according to the patient’s
response.
Analysis of Pulmonary Function
and Safety
Effectiveness and safety data were
retrospectively collected from patient notes at
3-month intervals. Pulmonary function
measurements, including %FVC and %DLCO,
were analyzed from 6 months before the start of
pirfenidone treatment up to 12 months of
treatment. Safety data were included for all
follow-up visits. Missing data were not imputed.
Decline in lung function was defined in the
same way as in the ASCEND study: an absolute
C10% decline in %FVC or death at week 52
(12 months). The proportion of patients with a
decline of C10% in %FVC from baseline or who
died was analyzed at 3 monthly intervals up to
12 months using all available data (no
censoring for missing data). A Kaplan–Meier
time-to-event analysis was additionally
undertaken, whereby patients with missing
data were censored at their last FVC
assessment (event defined as an absolute
C10% decline in %FVC or death). Where
available, %FVC and %DLCO data from
6 months prior to pirfenidone initiation were
collected and compared with baseline and
6-month values using a paired t test (SAS 9.2.
SAS Institute Inc., Cary, NC, USA).
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1975, as revised in
2000 and 2008. Patient permissions for data
collection and usage were granted according to
specific local requirements of the medical
ethical committee at each participating center.
Additional informed consent was obtained from
all patients for which identifying information is
included in this article.
RESULTS
Patients
Patient demographics and baseline
characteristics in the three centers (Center 1:
n = 29, The Netherlands; Center 2: n = 21,
Belgium; Center 3: n = 13, The Netherlands)
are reported in Table 1. Patients’ mean
[standard deviation (SD)] age at the start of
pirfenidone treatment was 66.8 (8.9) years in
the pooled cohort. A high percentage of
patients in each center were current or former
smokers and the majority were male (C80%).
Across all centers, 69.8% of patients had a high-
resolution computed tomography (HRCT) scan
showing a definite usual interstitial pneumonia
(UIP) pattern. In 46% of the patients, a surgical
lung biopsy was performed. Baseline mean (SD)
%DLCO and %FVC were 47.9% (12.4) and 75.0%
(16.5), respectively, for the pooled cohort.
Pirfenidone Administration
Dose escalation at treatment initiation was
followed as described [12], except for one
patient in Center 2 who remained on the initial
3 9 1 dose due to gastrointestinal (GI) AEs.
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Pulmonary Function
Among patients with complete FVC data
between 6 months prior to (-6 months) and
6 months after (6 months) initiation of
pirfenidone therapy (n = 32), the mean decline
in %FVC from -6 months to baseline (pre-
therapy) was 4.8% (p = 0.002) and from
baseline to 6 months (on therapy), 0.8%
(p = 0.516), giving a clear reduction in FVC
decline during the 6 months after pirfenidone
initiation (p = 0.082; Fig. 1). In a similar
analysis of %DLCO (n = 26), the decline from
-6 months to baseline was 6.7% (p = 0.003),
whereas from baseline to 6 months the decline
was lower (3.0%), but remained significant
(p = 0.033; Fig. 2) and did not differ
significantly from the decline in the 6 months
before pirfenidone initiation (p = 0.214).
A categorical analysis of %FVC was
undertaken in the above 32 patients with
complete %FVC data to investigate lung
function progression upon treatment with
pirfenidone; the proportion of patients with
\5% decline in FVC increased after therapy and
there were fewer patients with [10% FVC
decline than before therapy (Fig. 3).
Table 1 Patient characteristics
Center 1
(n5 29)
Center 2
(n5 21)
Center 3
(n5 13)
Pooled data
(n5 63)
Mean age at diagnosis (years ± SD) 67.3 ± 7.6 70.7 ± 9.6 59.5 ± 6.6 66.8 ± 8.9
Male [n (%)] 24 (82.8) 18 (85.7) 11 (84.6) 53 (84.1)
Smoking status [n (%)]
Never 7 (24.1) 3 (14.3) 2 (15.4) 12 (19.0)
Former 22 (75.9) 17 (81.0) 11 (84.6) 50 (79.4)
Lung physiological features (mean ± SD)
FVC - % of predicted value 76.1 ± 16.1 78.0 ± 17.1 67.8 ± 15.3 75.0 ± 16.5
DLCO - % of predicted value 51.1 ± 14.8 47.0 ± 8.4 42.8 ± 11.2 47.9 ± 12.4
Diagnostic ﬁnding on high-resolution computed tomography [n (%)]
Deﬁnite UIP on HRCT 19 (65.5) 18 (85.7) 7 (53.8) 44 (69.8)
Surgical lung biopsy 11 (37.9) 8 (38.1) 10 (76.9)a 29 (46.0)
DLCO carbon monoxide diffusing capacity, FVC forced vital capacity, HRCT high-resolution computer tomography, IPF
idiopathic pulmonary ﬁbrosis, SD standard deviation, UIP usual interstitial pneumonia
a Including two autopsies
Fig. 1 Mean FVC% predicted at -6 months (pre-
treatment), baseline, and 6 months on pirfenidone for
patients with FVC data at all of these time points
(n = 32). CI conﬁdence interval, FVC forced vital capacity
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The proportion of patients with FVC decline
C10% or death across four study time points
ranging from 3 to 12 months is illustrated in
Table 2. At 12 months, 4 patients had a C10%
decline in FVC compared with baseline; 35
patients remained stable, while 3 patients had
C10% increase in FVC compared with baseline
(Table 2). Ten patients had a C10% FVC decline
or death, which was 21% of patients treated
with pirfenidone for 12 months (10/48
patients).
Finally, a Kaplan–Meier plot of progression-
free survival over 12 months, incorporating
%FVC decline C10% from baseline or death, is
presented in Fig. 4. At 12 months, the estimated
progression-free survival rate was 0.78.
Mortality
Six (9.5%) patients died between baseline and
12 months (all-cause mortality). IPF was listed
as the cause of death in 5 (7.9%) patients.
Safety and Tolerability
A total of 57.1% of patients in the pooled cohort
experienced treatment-emergent AEs (Table 3),
with the frequency of treatment-emergent AEs
differing substantially between the centers
(82.8%, 38.1% and 38.5% of patients in
Centers 1, 2, and 3, respectively).
Loss of appetite and nausea were the most
frequent AEs, reported in 25.3% and 11.1% of
the pooled cohort, respectively.
Photosensitivity reaction (see example in
Fig. 5) and rash were reported in 9.5% and
6.3% of patients in the pooled cohort,
respectively.
A total of 12 patients (19%) in the pooled
cohort discontinued pirfenidone due to
treatment-emergent AEs (Table 4); nausea was
the most highly cited reason for
discontinuation due to AEs (7.9% of patients
in the pooled cohort). Other reasons for
discontinuation were deemed unrelated to
study drug, including six deaths (all-cause
mortality) and two lung transplantations.
Fig. 2 Mean DLCO % predicted at -6 months (pre-
treatment), baseline, and 6 months on pirfenidone for
patients with DLCO data at all of these time points
(n = 26). CI conﬁdence interval, DLCO diffusing capacity
of the lung for carbon monoxide
Fig. 3 Categorical analysis of %FVC change over
6-month intervals before and after start of pirfenidone
treatment for patients with FVC data at -6 months,
baseline, and 6 months (n = 32). %FVC forced vital
capacity - percentage of predicted value
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Management of AEs
Adverse event management was conducted on
an individual patient basis to facilitate
continued therapy whenever possible and
included pirfenidone dose reduction,
treatment of side effects, and/or
discontinuation according to the extent and
tolerability of AEs.
Table 2 Proportion of patients with stable (\10% change), increased (C10%), or decreased (C10%) %FVC relative to
baseline or death
Month 3 Month 6 Month 9 Month 12
na 58 53 41 48
Change in %FVC from baseline, n
Increased (C10%) 8 4 3 3
Stable (-10% to 10%) 44 44 33 35
Decreased (B-10%) 5 3 0 4
Death (cumulative), n 1 2 5 6
Patients C10% decline in %FVC or death
n 6 5 5 10
% 10.3 9.4 12.2 20.8
%FVC forced vital capacity - percentage of predicated value
a Data from patients who discontinued treatment or received a lung transplantation are not included, unless they
subsequently died during follow-up, and missing data are also not included. Patients not included in the analysis at each time
point are as follows (cumulative values for transplanted and discontinued, adjusted for subsequent death): month 3: 0
transplanted, 4 discontinued, 1 missing data; month 6: 0 transplanted, 6 discontinued, 4 missing data; month 9: 2
transplanted, 11 discontinued, 9 missing data; month 12: 2 transplanted, 10 discontinued, 3 missing data
Fig. 4 Kaplan–Meier of progression-free survival, incorporating %FVC decline C10% or death. Patients with missing data
were censored at the last FVC assessment. %FVC forced vital capacity - percentage of predicted value
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Following an AE, 41.2% of patients in the
pooled cohort experienced a period on a
modified dose of pirfenidone. Modified dosing
was prescribed to different extents across the
three centers, reflecting differences in the rate of
AEs reported in each of them (82.8%/58.3%,
38.1%/29.4%, and 38.5%/20% of patients
reported AEs/had dose modification in Centers
1, 2, and 3 respectively). Treatment
interruption, in contrast to lowering the dose,
usually led to prolonged or permanent
discontinuation of therapy. Two patients from
Center 1 who stopped treatment for at least
1 day after experiencing AEs were able to
resume dosing (and in one case a full dose)
after experiencing AEs.
DISCUSSION
A typical Phase III clinical study is well
defined to maximize chances of a reliable
outcome, generally involving clear inclusion
criteria (with limited co-morbidities and
concomitant medications), central review of
key disease parameters, and strict
management protocols. This always yields
the question: ‘‘To which extent can results
from clinical trials be extrapolated to daily
clinical practice?’’
In the discussion below, we put the
experience with pirfenidone obtained from
this clinical practice cohort of patients with
IPF into perspective by comparing it with data
from the recent Phase III ASCEND trial that was
ongoing at the time of this program.
Patient Population in Real-World Clinical
Practice
In this real-world cohort, age, sex, and smoking
habits were similar to patient characteristics in
ASCEND [11]. However, in the pirfenidone arm
of ASCEND, 95.7% of patients had a definite
pattern of UIP on HRCT, compared with 69.8%
of patients in our study. This is consistent with
other real-world evidence suggesting that about
half of patients with IPF do not have a definite
UIP pattern by HRCT [13].
Table 3 Patients reporting treatment-related AEs
AE Center 1 (n5 29) Center 2 (n 5 21) Center 3 (n5 13) Pooled data (n5 63)
All AEsa, n (%) 24 (82.8) 8 (38.1) 5 (38.5) 36 (57.1)
Upset stomach 2 (6.9) 2 (9.5) 1 (12.5) 5 (7.9)
Nausea 6 (20.7) 1 (4.7) 0 (0) 7 (11.1)
Loss of appetite/anorexia 12 (41.4) 2 (9.5) 2 (15.4) 16 (25.3)
Weight loss 2 (6.9) 0 (0) 0 (0) 2 (3.2)
Rash 3 (10.3) 1 (4.7) 0 (0) 4 (6.3)
Photosensitivity reaction 1 (3.4) 3 (14.2) 2 (15.4) 6 (9.5)
Pruritus 1 (3.4) 2 (9.5) 0 (0) 3 (4.7)
Fatigue 5 (24.0) 1 (4.7) 0 (0) 6 (9.5)
Dizziness 4 (13.7) 0 (0) 0 (0) 4 (6.3)
AEs adverse events
a Some patients reported more than one type of AE
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Notably, in ASCEND [11], 30.9% of patients
had a historical surgical lung biopsy, compared
with 46% of patients in our study. This
difference is likely related to the higher
percentage of patients with a definite UIP
pattern on HRCT in ASCEND compared with
our study.
Some differences in the patient populations
between ASCEND [11] and our cohort exist due
to real-world patients having co-morbidities
such as chronic obstructive pulmonary disease,
pulmonary embolism, and pulmonary
hypertension, which were mostly excluded
from the ASCEND trial. Indeed, strict rules are
applied in the selection of patients in clinical
trials, while a more pragmatic approach is often
adopted in daily clinical practice. As a result,
patients treated in a real-world setting typically
display less homogenous characteristics and
may have more co-morbidities and
concomitant medications than those enrolled
in clinical trials.
Notably, differences in patient characteristics
observed in the real world versus clinical trials
often arise due to differences in experience and
views across multidisciplinary teams that may
impact diagnosis. Indeed, unlike in our study,
the ASCEND trial included a central review,
which was conducted by reputable radiology
and pathology experts, allowing for an
integrated approach to diagnosis. A notable
gap in the diagnostic proficiencies between
community and academic experts has been
reported, resulting in recommendations for
patients to be referred to centers with
expertise in interstitial lung disorders [14].
Longitudinal Changes in Pulmonary
Function
Overall, our results suggest that pirfenidone has
a favorable effectiveness profile in a patient
cohort where a more pragmatic approach in
daily practice was undertaken, consistent with
the positive effect observed in clinical studies [9,
10, 15, 16]. Additionally, outcomes for patients
with data available from 6 months prior to
commencing pirfenidone treatment are similar
Fig. 5 Example of a photosensitivity reaction associated
with pirfenidone treatment in one patient from Center 1
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to those recorded in an observational cohort
study in Germany, which reported a reduction
in mean decline of %FVC after treatment start
(0.7 ± 10.9%) compared with the pre-treatment
period (6.6 ± 6.7%, p = 0.098) [17]. Similar
findings to those presented in the categorical
analysis of FVC decline (Fig. 3) were presented
by Bonella and colleagues [15].
The proportion of patients in this study who
had an FVC decline C10% or died by 12 months
was comparable with that reported in ASCEND
[11]. One limitation of this comparison is that
follow-up pulmonary function data for patients
who stopped treatment were not available, nor
was any imputation performed for missing
values. In the ASCEND study, missing values
for reasons other than death were imputed as
the average value for the three patients with the
smallest sum of squared differences in FVC
values at the prior visits; this method was not
feasible with the relatively limited number of
patients in our cohort. Nonetheless, if patients
who stopped treatment are excluded from our
analysis, the proportion of patients who had a
decline of C10% predicted FVC or who died at
12 months was 21%, which is comparable to the
proportion observed in the ASCEND study.
The 12-month Kaplan–Meier progression-
free survival estimate is consistent with that of
the alternative non-censored analysis presented
in Table 2. However, this estimate cannot be
directly compared with that obtained in the
ASCEND study where the composite end point
additionally included confirmed decrease of
50 m or more in the 6-min walk distance, a
parameter that could not be analyzed here
owing to a lack of standardized measurement
across centers and follow-up data [11].
Considering the increased probability of fatal
events as FVC decreases [11, 18], a reduced
Table 4 Reasons for pirfenidone treatment discontinuation
AE Center 1
(n5 29)
Center 2
(n5 21)
Center 3
(n 5 13)
Pooled data
(n5 63)
Patients discontinuing treatmenta, n 5 5 2 12 (19.0)
AEs, n
Upset stomach 2 0 0 2 (3.2)
Nausea 3 2 0 5 (7.9)
Loss of appetite/anorexia 0 1 0 1 (1.6)
Rashes 0 0 2 2 (3.2)
Severe photosensitivity 0 1 0 1 (1.6)
Diffuse pruritus 4 0 0 4 (6.3)
Fatigue 1 0 1 2 (3.2)
Death 0 2 4 6 (9.5)
Lung transplantation 1 1 0 2 (3.2)
Pooled cohort data are presented as n (%)
AE adverse events
a Some patients had more than one reason for treatment discontinuation
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decline in FVC in real-world practice with
pirfenidone is clinically important. Results
from du Bois and colleagues [18] demonstrate
that FVC is a reliable and valid parameter to
assess lung function; a decline in %FVC of
C10% at 6 months was associated with a nearly
fivefold increase in the risk of 1-year mortality,
and a decline of 5–10% conferred a more than
twofold increased risk of premature death.
Moreover, statistical analyses to assess minimal
clinically important difference found that small
changes in FVC (2–6%) were associated with
clinically relevant changes of disease status [18].
In the future, additional validated clinical
markers of IPF progression could enable
physicians to better define a patient’s
condition and the benefits of treatment.
Pirfenidone Safety and Tolerability
The nature of the AEs observed in this analysis
was consistent with those seen in Phase III trials
[9, 10] and other studies documenting clinical
experience with pirfenidone [15, 16]. Nausea
was one of the most frequently reported
treatment-emergent AEs in the pooled cohort
and was also the most prevalent AE in the
pirfenidone 2403 mg/day treatment group of
the CAPACITY and ASCEND trials [9, 11]. The
overall prevalence of AEs across the three
centers (57.1% of patients) was lower than
that reported in the CAPACITY and ASCEND
trials, where nearly all patients reported at least
one treatment-emergent AE [11]. This may be
due to the fact that the collection and reporting
of AEs were less formalized in this clinical
practice cohort. It is not clear whether a
difference in the prevalence of AEs between
the three centers was due to demographic
differences or differences in how AEs were
reported.
Management of AEs: Experience
and Practical Lessons
These data represent our first experiences with
prescribing pirfenidone. There was an inevitable
learning curve in the management of AEs,
which may have led to an elevated number of
treatment modifications and/or
discontinuations. This would be expected to
decrease as physicians become more
experienced. As shown recently in the
pirfenidone post-authorization safety registry
[19], in which adverse drug reactions were
managed by dose adjustment, patients with
dose adjustments were less likely to discontinue
treatment than those without (24.7% vs. 75.3%,
p = 0.002) and remained on therapy for a longer
period of time. Indeed, dose adjustment may
influence the long-term tolerability of
pirfenidone.
Sharing different approaches will be key to
optimizing treatment compliance and
pirfenidone-related AE management. We
recommend a flexible, tailor-made approach to
dose adjustments based on the severity of
observed AEs and responses to changes in dose
levels. We also emphasize that physicians
prescribing pirfenidone should repeatedly and
carefully consider the balance between side
effects and the efficacy of pirfenidone in
slowing lung function decline [11].
Since there are no general rules as to when
patients should be re-challenged following
temporary treatment interruption, the decision
to re-challenge must be made on an individual
basis according to patient needs and AE
severity. Adopting the optimal approach for
the individual patient would clearly be
facilitated by a higher frequency of patient
visits. A specialist nurse might also be involved
in the follow-up process and provide patient
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counseling leading to better titration and
tolerance of the drug [20].
Patient awareness and expectations
regarding pirfenidone therapy and its
associated AEs, such as pirfenidone-related
skin photosensitivity and GI side effects, is
crucial, as preventative measures could be
adopted to stop or minimize the severity of
these occurrences. To prevent GI side effects, it
is advised to take pirfenidone during a meal and
to even take the three capsules separately
throughout the meal. Dose reduction can also
be used to reduce GI side effects. Proton pump
inhibitors and prokinetics also seem to reduce
GI side effects in clinical experience [21].
Whereas some tolerance may occur with GI
side effects, the photosensitivity reaction can
occur at any time regardless of the length of
therapy, and therefore patients should be
vigilant about sun exposure.
In treating patients with IPF, the balance
between disease-centered care and palliation
should constantly be evaluated. Patient needs
should be identified [22, 23] and integrated into
better patient-reported outcomes to help
health-care professionals optimize patients’
quality of life.
Many of the patients reported in this analysis
are still receiving treatment and additional
results will be evaluated following longer
follow-up periods.
Limitations
The retrospective nature of this analysis limited
the clinical parameters which could be
meaningfully analyzed. There were no pre-
specified protocols for evaluating the 6-min
walk test, dyspnea, and acute exacerbations of
IPF. Defining and following protocols to
rigorously evaluate these parameters is difficult
to manage even in prospectively planned
multicenter clinical trials [24]. There was also
no systematic measurement of these parameters
during follow-up. The sporadic data collected
for these parameters are not presented.
The results from this cohort reflect daily
clinical experience and should be considered
instructional. All analyses of pirfenidone
effectiveness are exploratory due to their
uncontrolled and open nature. Since missing
data were not imputed and final analysis was
conducted on study completers, inferences
derived from these data are vulnerable to
selection bias.
Open Questions
The timing of pirfenidone treatment initiation
in patients with IPF remains an open question.
Many experts in the field are convinced that
early treatment is mandatory [25]. Furthermore,
it has been shown that FVC decline correlates
with an increased risk of mortality [15],
suggesting that treatment should be initiated
in a timely manner, when lung function is still
preserved and before IPF progression accelerates
[11].
CONCLUSIONS
Data supporting the real-world benefit of
pirfenidone use in everyday clinical practice
are beginning to emerge and appear to mirror
results of large controlled clinical trials. Indeed,
in this cohort study, pirfenidone showed a
safety and effectiveness profile not dissimilar
to that observed in the recently published
ASCEND study. These real-world clinical data
may help to further educate physicians who
lack experience in managing a patient with IPF
receiving pirfenidone treatment and, in turn,
support better patient outcomes.
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